Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
News|Videos|July 28, 2023
Dr Husain on Developments in ALK+ NSCLC
Author(s)Hatim Husain, MD
Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.
Advertisement
Hatim Husain, MD, medical oncologist and assistant professor of medicine at Moores Cancer Center of the University of California, San Diego, discusses developments in ALK-positive non–small cell lung cancer.
Advertisement
Related to this article
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
4
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
5